Replies to post #33526 on Marker Therapeutics Inc (MRKR)

[GMA13]

ROCKON Lymphoma & AML-Adjunct.
…….. and maybe the current regime for Pancreatic Cancer will do more than just adding 1 new Antigen & expecting a different test result outcome!

[learningcurve2020]

A consultant...Geron...Ugh. We'll see.

>>Dr. Stuart joins Marker Therapeutics as a consultant after having most recently worked as interim Chief Medical Officer, Head of Clinical Development or Clinical Advisor for numerous biotechnology and pharmaceutical companies worldwide. In this capacity, Dr. Stuart was responsible for leading each company's clinical strategy including clinical development plans, Phase 1-3 study designs, and protocol development for a variety of benign and malignant hematologic, solid tumor, and supportive care indications. Dr. Stuart previously served as Vice President of Clinical Development at Geron Corporation, where she spearheaded efforts to develop a telomerase inhibitor in myeloid malignancies. Before her role at Geron Corp., she worked at Genentech Inc. as a Senior Medical Director in the Oncology Division. During her time at Genentech, she served in leadership position for multiple early and late-stage hematology/oncology programs.

Prior to Genentech, Dr. Stuart served as an attendi